Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (162)

1

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

enthalten in: BMC infectious diseases | 2024

von Patel, V. | Levick, B. | Boult, S. | +5

2

Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir) : a retrospective cohort study

enthalten in: BMC pharmacology & toxicology | 2024

von Yalan, Q. | Lingfang, H. | Xisong, L. | +3

3

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 : Evidence from the US National COVID Cohort Collaborative (N3C)

enthalten in: Clinical drug investigation | 2024

von Bell, C. | Bobbili, P. | Desai, R. | +9

4

Kinetics of Trisulfide-to-Disulfide Conversion of Therapeutic IgG1 Monoclonal Antibodies Under Physiological Conditions : A Case Study of Casirivimab And Imdevimab

enthalten in: Journal of pharmaceutical sciences | 2024

von Zhong, X. | Gao, L. | Kleinberg, A. | +5

5

Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019

enthalten in: American journal of perinatology | 2024

von Buonomo, A. | Filippo, I. | Esposito, N. | +7

6

A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity

enthalten in: Nature communications | 2024

von de Campos-Mata, L. | Trinité, B. | Modrego, A. | +22

7

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1 : a multicentre, retrospective cohort study

enthalten in: BMC research notes | 2024

von Lo, C. | Lo, C. | Komorowski, A. | +8

8

Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice

enthalten in: Experimental dermatology | 2024

von Zhou, J. | Yuan, Y. | Liu, Y. | +7

9

Anifrolumab : first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

enthalten in: Expert review of clinical immunology | 2024

von Gensous, N. | Lazaro, E. | Blanco, P. | +1

10

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages

enthalten in: PLoS pathogens | 2023

von Li, L. | Chen, X. | Wang, Z. | +4

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]